PSB-24379 

PSB-24379 is a CD39 inhibitor that potently inhibits human membrane-bound CD39 (K_i = 77.4 nM) and truncated soluble human CD39 (K_i = 23.1 nM). PSB-24379 reduces the level of ATP hydrolysis in melanoma and breast cancer cell membranes. PSB-24379 partially reverses ATP-mediated suppression of T cell activation and proliferation in a high-ATP environment. PSB-24379 can be used in research related to melanoma and breast cancer^[1].

PSB-24379 potently inhibits both human membrane-bound CD39 (Ki = 77.4 nM) and truncated soluble human CD39 (Ki = 23.1 nM)^[1].
PSB-24379 inhibits human CD73 with a K_i of 240 nM^[1].
PSB-24379 reduces ATP hydrolysis activity in membrane preparations from human Ma-Mel-65 melanoma cells and human MDA-MB-231 triple-negative breast cancer cells^[1].
PSB-24379 partially reverts ATP-mediated suppression of T cell activation in primary human peripheral blood mononuclear cells in an ATP-rich environment^[1].
PSB-24379 exhibits high metabolic stability in human and mouse liver microsomes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

637.64

C₃₀H₃₂N₅O₇PS

O[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(NCCCCC4=CC=CC=C4)=C3N=C2SC5=C(C=CC=C6)C6=CC=C5)O[C@@H]1COP(O)(O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Bi C, et al. Nucleotide-Derived Competitive Inhibitors of Ectonucleotidase CD39─A Promising Extracellular Target for Immunotherapy of Cancer. J Med Chem. 2026;69(9):10828-10864.